When President Donald Trump signed into law a dying patient’s right to pursue unapproved treatments without FDA oversight, he called it “a bill for the people,” adding he did it without regard for insurers and drug companies.
“I don’t care about them. I really don’t,” Trump said during the bill signing about a month ago for legislation known as “right to try” (Pub. L. 115-176).
The president may not care about insurers, but their decisions on how to handle right-to-try coverage could determine whether patients are taking on financial risks as well as health risks.
“Medicare doesn’t ...